Sensorion 将来の成長

Future 基準チェック /26

Sensorionの収益は年間22.3%で減少すると予測されていますが、年間収益は年間44.9%で増加すると予想されています。EPS は年間1.7%で増加すると予想されています。

主要情報

-22.3%

収益成長率

1.7%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	44.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 May 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

BST:RFM - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8	-40	N/A	N/A	2
12/31/2025	14	-37	-40	-39	3
12/31/2024	14	-24	-21	-20	3
12/31/2023	6	-22	-21	-21	N/A
9/30/2023	6	-23	-22	-21	N/A
6/30/2023	6	-23	-23	-22	N/A
3/31/2023	5	-23	-23	-22	N/A
12/31/2022	5	-23	-23	-21	N/A
9/30/2022	5	-22	-19	-18	N/A
6/30/2022	5	-21	-15	-14	N/A
3/31/2022	4	-18	-13	-13	N/A
12/31/2021	4	-15	-11	-11	N/A
9/30/2021	4	-13	-12	-11	N/A
6/30/2021	3	-11	-13	-12	N/A
3/31/2021	3	-10	-9	-9	N/A
12/31/2020	2	-9	-5	-5	N/A
9/30/2020	2	-10	-8	-8	N/A
6/30/2020	2	-11	-11	-11	N/A
3/31/2020	2	-12	-12	-12	N/A
12/31/2019	2	-12	-14	-14	N/A
9/30/2019	2	-12	-12	-12	N/A
6/30/2019	2	-12	-9	-9	N/A
3/31/2019	2	-12	-11	-11	N/A
12/31/2018	2	-12	-13	-12	N/A
9/30/2018	2	-12	-11	-11	N/A
6/30/2018	2	-11	-10	-9	N/A
3/31/2018	2	-10	-9	-9	N/A
12/31/2017	2	-10	-8	-8	N/A
9/30/2017	1	-9	N/A	N/A	N/A
6/30/2017	0	-8	N/A	N/A	N/A
3/31/2017	0	-8	N/A	N/A	N/A
12/31/2016	0	-7	N/A	N/A	N/A
9/30/2016	0	-7	N/A	N/A	N/A
6/30/2016	1	-7	N/A	-8	N/A
3/31/2016	0	-6	N/A	-6	N/A
12/31/2015	0	-4	N/A	-5	N/A
9/30/2015	0	-4	N/A	N/A	N/A
6/30/2015	0	-3	N/A	-3	N/A
3/31/2015	0	-3	N/A	-3	N/A
12/31/2014	0	-3	N/A	-2	N/A
12/31/2013	0	-2	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RFM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RFM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RFM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RFMの収益 ( 44.9% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: RFMの収益 ( 44.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RFMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Sensorion 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation

Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

Sensorion SA announced that it expects to receive €4.999999 million in funding from Sonova Holding AG

Sensorion and Novasep Announce Signature of A Gene Therapy Product Development and Manufacturing Agreement

Sensorion SA has completed a Follow-on Equity Offering in the amount of €31.0012 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘